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Abstract
Janus kinase-signal transducer and activator of transcription (JAK/STAT) signalling, pivotal in Philadelphia-negative (Ph-ve) myeloproliferative
neoplasm (MPN), is negatively regulated by molecules including SOCSs, CISH and SHP1. SOCS1, SOCS2 and SOCS3 methylation have been
studied in MPN with discordant results. Herein, we studied the methylation status of SOCS1, SOCS2 and SOCS3, CISH and SHP1 by methyla-
tion-specific polymerase chain reaction (MSP) in cell lines and 45 diagnostic marrow samples of Ph-ve MPN. Moreover, we attempted to
explain the discordance of methylation frequency by mapping the studied MSP primers to the respective genes. Methylation was detected in
normal controls using SOCS2 MSP primers in the 3′translated exonic sequence, but not primers around the transcription start site in the 5′
untranslated regions (5′UTR). SOCS1, SOCS2, SOCS3 and CISH were completely unmethylated in primary MPN samples and cell lines. In con-
trast, methylation of SHP1 was detected in 8.9% primary marrow samples. Moreover, SHP1 was completely methylated in K562 cell line, lead-
ing to reversible SHP1 silencing. A review of methylation studies of SOCS1 and SOCS3 showed that spuriously high rates of SOCS methylation
had been reported using MSP primers targeting CpG sites in the 3′translated exonic sequence, which is also methylated in normal controls.
However, using MSP primers localized to the 5′UTR, methylation of SOCS1, SOCS2 and SOCS3 is infrequent across all studies. In summary,
methylation of SOCS1, SOCS2, SOCS3 and CISH is infrequent in Ph-ve MPN. Appropriate MSP primers are important for accurate estimation of
the methylation frequency. The role of SHP1 methylation in the pathogenesis of MPN warrants further investigation.
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Introduction
Philadelphia-negative (Ph-ve) myeloproliferative neoplasm (MPN) is a
stem cell disease with proliferation of myeloid compartment, leading
to development of distinct clinical entities such as polycythemia vera
(PV), essential thrombocythemia (ET) and primary myelofibrosis
(PMF) [1,2]. Recently, Janus kinase 2 (JAK2) V617F mutation was
detected in most of the patients with PV and about half of the patients
with ET and PMF, leading to constitutive activation of Janus kinase-
signal transducer and activator of transcription (JAK/STAT) signalling
[3,4]. However, pathogenesis in those without JAK2 V617F mutation
remains unknown.
The JAK/STAT signalling pathway is important for the transmis-
sion of cytokine signals from cell surface to the nucleus [5]. Binding
of cytokines to their cognate receptors results in the dimerization of
receptor complexes and activation of the Janus family of protein tyro-
sine kinases [6, 7], followed by phosphorylation of the cytoplasmic
STATs. Upon phosphorylation, STATs form homo- or hetero-dimers
migrate to the nucleus and activate gene transcription. This JAK/STAT
pathway is subject to negative regulation by PIAS members, JAK
inhibitors like SOCS family proteins and protein tyrosine phosphata-
ses (PTP) such as SHP1 [6–8]. The SOCS family comprises eight
members, including SOCS1-7 and CISH, and is characterized by the
presence of a central Src homology (SH2) domain that is flanked by a
variable length N-terminal domain, and a conserved 40 amino acid
carboxy terminal ‘SOCS box’ domain [6, 7]. SOCS proteins suppress
JAK/STAT signalling by binding with their SH2 domain to phosphoty-
rosine residues in cytokine receptors or activated JAKs [9]. Among
them, CISH, localized at 3p21.2; SOCS1, at 16p13.13; SOCS2 at
12q22; and SOCS3 at 17q25.3 are most thoroughly studied in haema-
tological malignancies. SOCS1 and SOCS3 can bind the activated
JAKs and cytokine receptors, respectively, through SH2 domain to
inhibit JAK tyrosine kinase activation. CISH and SOCS2 inhibit STAT
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activation by binding to phosphorylated tyrosine residues on activated
cytokine receptors and compete with STAT or hinder the STAT-bind-
ing sites of receptors [9]. SOCS members are cytokine-inducible neg-
ative regulators of the cytokine signalling [9]. SOCS1, SOCS2, SOCS3
and CISH can be induced by a multitude of cytokines, and hence
serve as negative feedback to curb excessive cytokine signalling [9].
SOCS1 and SOCS3 comprise two exons with the first exon being
untranslated, whereas SOCS2 consists of three exons with the first
exon being untranslated [10–12]. All these three genes are embedded
in a huge CpG island of more than two kilobases extending from the
5′UTR to the 3′translated exonic sequence, as demonstrated in the
corresponding websites in NCBI NIH Roadmap Epigenomics project
[13].
SHP1, also known as HCP, SHPTP1 and PTP1C, is a 68-kd, cyto-
plasmic PTP [14]. The human SHP1 gene is located on chromosome
12p13, consists of 17 exons and spans ~17 KB of DNA. It contains
two tandem Src homology (SH2) domains, a catalytic domain and a
C-terminal tail of about 100 amino acid residues [14]. In contrast to
the ubiquitous expression of the structurally related SHP2, SHP1 is
primarily expressed in haematopoietic cells, and considered a putative
tumour suppressor gene in lymphoma and leukaemia, as it antago-
nizes the growth-promoting and oncogenic potentials of protein tyro-
sine kinase [14].
Hypermethylation of promoter-associated CpG islands of tumour
suppressor genes and recently microRNA [15–17], resulting in gene
silencing, and hence inactivation of tumour suppressor genes, has
been implicated in the pathogenesis of haematological malignancies
[18]. Moreover, aberrant DNA methylation of SOCS1, SOCS2, SOCS3
and SHP1 has been studied in Ph-ve MPN with discordant results
[19–23]. Our previous study has shown that while normal cells pos-
sess unmethylated CpG islands around the transcription start site
(TSS) in the 5′UTR, CpG sites inside the coding exonic sequence are
methylated for SOCS1, thereby emphasizing the importance of meth-
ylation-specific polymerase chain reaction (MSP) primer selection
[24, 25]. Moreover, there is scanty data on the methylation of CISH in
Ph-ve MPN. In this study, we investigated the methylation profile of
SOCS1, SOCS2, SOCS3, CISH and SHP1 in MPN by the use of MSP
primers in the both 5′UTR and translated exonic sequence of the
genes. Finally, we attempted to explain the discordance of methylation
frequency of SOCS1 and SOCS3 in MPN by mapping the studied MSP
primers to the respective genes.
Materials and methods
Patient samples
DNA was extracted from primary bone marrow samples at diagnosis of
45 patients with Ph-ve MPN. Diagnosis of Ph-ve MPN including ET, PV
and PMF was based on WHO criteria. MSP on DNA extracted from pri-
mary marrow samples at diagnosis was performed on 45 patients with
MPN [ET, N = 34 (75.6%); PV, N = 7 (15.6%) and PMF, N = 4
(8.9%)]. The clinical features of these patients have been previously
described [26–28]. In brief, there were 24 (53.5%) male and 21
(46.7%) female patients with a median age of 67.5 years (range: 28–
89 years) The median presenting platelet count of 848 9 109/l, present-
ing Hb of 9–22 g/dl (median 13.3 g/dl), median presenting leucocyte
count of 14.4 9 109/l (range: 7–28 9 109/l). Apart from 5 (11.1%)
patients in whom the presenting symptoms was unavailable, 25
(62.5%) were asymptomatic at diagnosis, 4 (10%) with bleeding, 4
(10%) with erythromelalgia, 2 (5%) with minor stroke, 3 (7.5%) with
abdominal pain and one each (2.5%) with blurred vision and weight
loss. JAK2 V617F mutation was presented in 26 of the 40 patients.
DNA from three normal bone marrow donors and five normal peripheral
blood donors was used as negative control, while enzymatically methy-
lated control DNA (CpGenome Universal Methylated DNA, Millipore,
Billerica, MA, USA) was considered as positive control. The study has
been approved by Institutional Review Board of Queen Mary Hospital,
and written informed consent has been obtained.
Cell lines and culture
Cell lines and culture were described in previous study [28]. SET-2 cells
were purchased from Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (DMSZ) (Braunschweig, Germany). HEL cells is a
human erythroleukemia cell line generously provided by Dr Zhang Dong-
Er, Department of Pathology and Molecular Biology, Moores Cancer Cen-
ter, University of California San Diego, USA. MEG-01 and K562 cells were
kindly provided by Dr Mo Yang, Department of Paediatrics, Queen Mary
Hospital, The University of Hong Kong, Hong Kong. SET-2 was derived
from ET at megakaryoblastic leukaemic transformation. HEL was derived
from peripheral blood of a patient with erythroleukemia. Both SET-2 and
HEL carried JAK2 V617F mutation. MEG-01 and K562 were derived from
blastic transformation of patients with CML and carried BCR/ABL fusion
gene. Cell cultures were cultured in RPMI-1640 medium (Invitrogen,
Carlsbad, CA, USA), supplemented with 10% foetal bovine serum (20%
for SET-2; Invitrogen), 50 U/ml penicillin and 50 lg/ml streptomycin
(Invitrogen) in a humidified atmosphere of 5% CO2 at 37°C.
Methylation-specific polymerase chain reaction
DNA extraction from bone marrow samples, peripheral blood and cell
lines was performed with QIAamp DNA Blood Mini Kit according to the
manufacturer’s instructions. DNA bisulphite conversion was performed
with a commercially available kit (EpiTect Bisulfite Kit, Qiagen, Duessel-
dorf, Germany). Methylation status of SOCS1, SOCS2, SOCS3, CISH and
SHP1 gene promoter CpG islands was investigated by MSP as
previously reported [24]. Primers used for the methylated MSP (M-
MSP) and unmethylated MSP (U-MSP) were listed in the Table S1. For
SOCS1, based on our previous study [24], MSP primer inside exon 1
was methylated in normal controls, and hence unsuitable for methylation
analysis. In contrast, MSP primers upstream of the translation start
region (MSP-5′) were unmethylated in normal controls, and hence used
in this study. For SOCS2, two sets of primers, located 5′ (SOCS2-5′) and
3′ (SOCS2-3′) to the translation start site of SOCS2 were used in this
study. SOCS2-5′ primers were used according to previous study [29].
SOCS2-3′ primers were mapped to the region, in which methylation of
SOCS2 has been studied by bisulphite genomic sequencing and methyla-
tion-sensitive restriction enzyme assay in MPN patients samples by
Quentmeier et al. [30]. SOCS3 primers were adopted from He et al.
[31]. All MSP were performed in thermal cycler (9700, Applied
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Biosystems, Foster City, CA, USA) under the conditions: 95°C for
10 min., followed by specific cycles of 95°C for 30 sec., specific anneal-
ing temperature for 30 sec., 72°C for 30 sec. and a final extension of
10 min. at 72°C (Table S1). The MSP mixture contained 30 ng of bisul-
phite-treated DNA, 0.2 mM dNTPs, MgCl2 (Table S1), 10 pmol of each
primer, 19 PCR buffer and 1 unit of FastStart Taq DNA polymerase
(Roche, Mannheim, Germany) in a final volume of 25 ll. Ten microlitre
of PCR products was loaded onto 6% polyacrylamide gels, electrophore-
sed, stained with ethidium bromide and visualized under ultraviolet light.
5-Aza-2′-deoxycytidine (5-AzadC) treatment of
the cell line K562
K562 cells were completely methylated for SHP1. For treatment with 5-
AzadC, K562 cells (1 9 106 cells/ml) were seeded into six-well plates
on day 0 and cultured with 0.5 lM of 5-AzadC from day 1 to day 3.
Cells on day 0 and day 3 of treatment were harvested.
Reverse transcription-PCR for SHP1
MirVanaTM miRNA Isolation Kit (Ambion, Austin, TX, USA) and Quanti-
Tect Reverse Transcription kit (Qiagen, Duesseldorf, Germany) were
used for isolation of total RNA and RT-PCR, respectively, according to
the manufacturers’ instructions. For SHP1 RT–PCR, the following prim-
ers: forward 5′-GGC ACT GGG AGC TGC ATC TGA GGC-3′; reverse 5′-
CTC GCA CAT GAC CTT GAT GTG-3′ were used. For GAPDH RT–PCR,
the following primers: forward 5′-ACC ACA GTC CAT GCC ATC ACT-3′;
reverse 5′-TCC ACC ACC CTG TTG CTG TA-3′ were used.
Statistical analysis
Correlation between SHP1 gene methylation status and the presence of
JAK2 V617F mutation was computed by the Chi-square test (or Fisher
Exact test) using Statistical Package for the Social Sciences (SPSS,
IBM, New York, NY, USA) version 18.0. All P values were two-sided.
M  B PB1  PB2 PB3  PB4   PB5  PC
U-MSP: SOCS2-3’M-MSP: SOCS2-3’
M  B PB1  PB2 PB3  PB4 PB5  PC
PB1
PC
PB2
PB3
PB4
A
B
Fig. 1 (A) Methylation-specific PCR of normal controls using SOCS2-3′ methylation-specific polymerase chain reaction (MSP) primers. M-/U-MSP
analysis showed that four of five normal peripheral blood controls (PB1-5) were methylated with the SOCS2-3′ primers. (M: DNA marker; B: blank;
PC: positive control; PB, normal peripheral blood control). (B) Sequencing of MSP products using SOCS2-3′ MSP primers in normal controls and
positive control showing methylation signals. Methylated cytosine residues [C] in CpG dinucleotide remained as C, whereas unmethylated cytosine
read as [T] after bisulphite conversion. (PC: positive control; PB: normal peripheral blood control).
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Results
Controls
As mentioned in the section for materials and methods, two sets of
MSP primers, one in the 5′UTR and the other in the 3′translated exon
sequence, were available for SOCS1 (SOCS1-5′ and SOCS1-3′) and
SOCS2 (SOCS2-5′ and SOCS2-3′). SOCS1-3′ has been shown to be
methylated in normal controls [24], and hence SOCS1-5′ MSP prim-
ers was used in this study. Using the MSP primers in the 5′UTR near
the TSS as described previously, SOCS1 was unmethylated in normal
controls, but methylated in the positive control [24]. For SOCS2,
using downstream MSP primers inside the translated exonic
sequence, i.e. SOCS2-3′, methylation was detected in four of five
normal control DNA samples (Fig. 1A). Moreover, sequencing of the
M-MSP products confirmed authenticity of methylation in these
normal controls, which was demonstrated by the presence of
Fig. 2Methylation-specific polymerase
chain reaction (MSP) of SOCS1, SOCS2-
5′, SOCS3, CISH and SHP1 in normal con-
trols. M-/U-MSP analysis showed that
three normal peripheral blood controls
(PB1-3) and three bone marrow controls
(BM1-3) were unmethylated with the
SOCS1, SOCS2-5′, SOCS3, CISH and
SHP1 primers. (M: DNA marker; B: blank;
PC: positive control; PB, normal peripheral
blood control; BM: normal bone marrow
control).
Fig. 3Methylation-specific polymerase
chain reaction of SOCS1, SOCS2-5′,
SOCS3, CISH and SHP1 in cell lines. For
SHP1, K562 was homozygously methylat-
ed, while HEL, SET-2 and MEG-01 were
completely unmethylated. HEL, SET-2,
MEG-01 and K562 were completely un-
methylated for SOCS1, SOCS2-5′, SOCS3
and CISH. (M: DNA marker; B: blank; PC:
positive control; N: normal control; C1:
HEL; C2: MEG-01; C3: SET-2; C4: K562).
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unconverted, and hence methylated, cytosine molecules at ‘CpG’
dinucleotide (Fig. 1B). On the other hand, using MSP primers in the
5′UTR near the TSS, SOCS2-5′ MSP primers, SOCS2 was unmethylat-
ed in all of the normal control samples, but methylated in the positive
control DNA (Fig. 2). Therefore, we studied methylation of the SOCS2
gene using MSP with primer set in the 5′UTR near the TSS instead of
inside the translated exon sequence. For the SOCS3, SHP1 and CISH
genes, M-MSP was negative in normal DNA, while positive for the
methylated control DNA. Conversely, U-MSP was positive in normal
DNA, while negative for the methylated control DNA (Fig. 2).
Sequencing of the M-MSP products of these four genes from the
methylated control DNA showed the expected nucleotide changes,
and hence confirmed complete bisulphite conversion and specificity
of MSP primers.
Cell lines
SHP1 was homozygously methylated in K562, but completely unme-
thylated in HEL, MEG-01 and SET-2. On the other hand, SOCS1,
SOCS2, SOCS3 and CISH genes were completely unmethylated in
these four cell lines (Fig. 3).
Primary samples
Methylation-specific polymerase chain reaction was performed in 45
primary samples of Ph-ve MPN patients for these five genes. None of
the patients carried hypermethylation of SOCS1, SOCS2, SOCS3 and
CISH (Fig. 4A). Nevertheless, methylation of SHP1 was found in four
M-MSP: SHP1 U-MSP: SHP1
M-MSP: SOCS1
M-MSP: SOCS2-5’
U-MSP: SOCS1
M-MSP: SOCS3
U-MSP: SOCS2-5’
M-MSP: CISH U-MSP: CISH
U-MSP: SOCS3
M B  N  S1  S2  S3  S4 S5 S6  S7  S8 PC M B  N  S1  S2  S3 S4 S5 S6  S7 S8 PC
M B  N  S1  S2  S3  S4 S5 S6  S7  S8 PC
M B  N  S1  S2  S3  S4 S5 S6  S7  S8 PC
M B  N  S1  S2  S3  S4 S5 S6  S7  S8 PC
M B  N  S1  S2  S3  S4 S5 S6  S7  S8 PC
M B  N  S1  S2  S3 S4 S5 S6  S7 S8 PC
M B  N  S1  S2  S3 S4 S5 S6  S7 S8 PC
M B  N  S1  S2  S3 S4 S5 S6  S7 S8 PC
M B  N  S1  S2  S3 S4 S5 S6  S7 S8 PC
B
A
Wild-type sequence:
Sequence of SHP1 M-MSP product of positive control:
Sequence of Methylated SHP1 M-MSP product of primary sample number 45:
T    T    C    G   A  T   G   A  T   A    G  T    T   G   T   T   A  T   C    G  T   T A   T   T  A  T    T     G  T   T   A  T   T  A    G   C    G  T    G   G  G   T   T  A
T   T   C   G  AT   G  A T A  G T   T  G T   T A T  C   G T  T A  T  T  A T   T  G T   T  A T   T  A  G  C   G T   G  G  G T    T A
C  T     C    G A   T    G    AC  A  G T     T  G T   C  A  C  C     G  C  C A  T    C  A T     T    G   T   T   A  T    T A   G   C    G  T   G    G  G    C  C A
Fig. 4Methylation-specific polymerase
chain reaction (MSP) of SOCS1, SOCS2-
5′, SOCS3, CISH and SHP1 in MPN pri-
mary samples. (A) M-/U-MSP analysis
showed that for SOCS1, SOCS2-5′,
SOCS3, CISH, methylation was absent in
MPN marrow samples, whereas for SHP1,
methylation was found in four MPN
patients. (M: DNA marker; B: blank; PC:
positive control; N: normal control; S: pri-
mary sample). (B) DNA sequencing of
SHP1 M-MSP products from bisulphite-
converted methylated positive and MPN
primary samples showing methylated
cytosine [C] residues in CpG dinucleotide
remained unchanged, unmethylated C res-
idues were converted into [T], whereas all
the non-CpG C residues were unmethylat-
ed and were converted to thymidine [T].
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ET patients, which was confirmed by direct sequencing of M-MSP
products of positive control and primary samples (Figs 4A and B). Of
these, three (75%) patients carried JAK2 V617F mutation. Two were
female. The median age was 63.3 years. There was no association of
SHP1 methylation and JAK2 V617F mutation (P = 0.99). One
presented with cerebral infarction, one with peptic ulcer and the other
two were asymptomatic at diagnosis. The median diagnostic Hb was
12.7 g/dl, platelet 962 9 109/L and leucocyte 15.4 9 109/L. Median
survival was 48.6 months. At the time of writing, two had died, one of
cerebral infarction and the cause of death of the other was unknown.
No myeloid transformation had occurred.
5-AzadC treatment of K562 cells
Untreated K562 cell line showed complete methylation of SHP1.
Treatment of cells with 0.5 lM 5-AzadC for 3 days led to deme-
thylation of SHP1 as demonstrated by the emergence of SHP1 U-
MSP signal (Fig. 5A). Moreover, RT–PCR demonstrated that SHP1
gene was re-expressed after 5-AzadC treatment of K562 cells
(Fig. 5B).
Discussion
To account for the discrepancy among the frequency of methylation
of SOCS1, SOCS2 and SOCS3 in MPN, we have mapped the MSP
primers used in different studies onto the gene map of SOCS1,
SOCS2 and SOCS3 (Figures S1–3; Table 1) and derived the following
observations.
Firstly, SOCS1, SOCS2 and SOCS3 genes have multiple exons
with the first exon being untranslated. Moreover, all of them are
embedded in a huge CpG island spanning >2 kb that extends from
the 5′UTR into the 3′translated protein-coding exonic sequences (Fig-
ures S1–3).
In a previous study, we have shown that using MSP primers of
SOCS1-3′ located in the translated exon 2, as described by Watanabe
et al. [32], methylation was detected in six of 12 normal peripheral
blood and two of three normal marrow samples [24]. These results
were confirmed by sequencing, suggesting that methylation within
SOCS1 exon 2 might not be involved in the regulation of gene tran-
scription. The lack of impact of SOCS1 exon 2 methylation on gene
expression has been illustrated in HL60 and U937 cell lines, in which
complete methylation of CpG islands within SOCS1 exon 2 was asso-
ciated with significant expression of SOCS1 [32] (Figure S1), and
hence a lack of correlation between methylation of CpG sites in the 3′
translated exonic sequence and gene silencing. On the contrary,
methylation of CpG islands in the 5′UTR, using MSP primer targeting
CpG sites in the 5′UTR, has been shown to be associated with inhibi-
tion of expression of, and hence silencing of SOCS1 by immunohisto-
chemistry in hepatoblastoma [33]. Therefore, methylation of SOCS1
should be studied with MSP primers mapping to the 5′UTR (SOCS1-
5′) as performed in this study. Using this SOCS1-5′ MSP primers,
SOCS1 methylation was not detected in any primary MPN samples or
cell lines. Similarly, other studies using primers targeting CpG sites in
the 5′UTR also showed that none of a total of 112 MPN cases (73 in
Fourouclas et al. and 39 in Fernandez-Mercado et al.) had methyla-
tion of SOCS1 [21, 22] (Figure S1). In contrast, studies using MSP
primers inside the 3′translated exonic sequence showed methylation
frequencies ranging from 12.8% to 72% (median: 14.5%) [20–23,
29, 34] (Figure S1). Therefore, these findings were consistent with
the notion that a boundary exists between methylated and unmethy-
lated CpG dinucleotide within a CpG island, and that CpG dinucleotide
inside the 3′translated protein-coding sequences is commonly methy-
lated in normal cells.
Similarly, SOCS2 methylation has been reported to be frequently
methylated in MPN [30]. In contrast, using MSP primers near the
TSS in the 5′UTR, we and others found the absence of SOCS2 methyl-
ation [19, 29]. Quentmeier et al., using methylation-sensitive
enzymes targeting CpG sites inside the 3′translated exon 2 sequence,
showed that 28.6% of MPN patients had methylation of SOCS2 [30]
(Figure S2). In this study, we have designed MSP primers mapping
to the same exon 2 sequence, and confirmed that CpG sites in this
region is in fact methylated in normal controls, and hence unimpor-
tant for epigenetic regulation of SOCS2 transcription, and unsuitable
for methylation study.
Moreover, using MSP primers close to the TSS in the 5′UTR (Fig-
ure S3), we and others showed infrequent methylation of SOCS3 in
MPN (this study, 0%; Fourouclas et al., 27%; Teofilli et al., 13.5%
and Fernandez-Mercado et al., 7.7%) [21, 22, 29], in contrast to fre-
quent methylation of 41.1% samples when MSP primers inside the
translated exonic DNA sequence were used [20]. In our study, we
adopted MSP primers from He et al. [31] near the TSS (Figure S3)
for several reasons. Firstly, our MSP primers were located close to
the TSS in the 5′UTR region. Secondly, methylation in CpG islands
within this region has been shown to be associated with SOCS3
silencing and aberrant activation of JAK/STAT signalling in lung
cancer cell lines, and hence biologically relevant [31]. Using MSP
primers in the 5′UTR, SOCS3 methylation was not detected in any of
the patients with PV or ET [22]. However, Fourouclas et al. demon-
A
B
Fig. 5 Effect of 5-AzadC treatment on K562 cells. (A) M-/U-methylation-
specific polymerase chain reaction analysis of SHP1 promoter methyla-
tion status showed that 5-AzadC treatment led to progressive demethy-
lation of SHP1 promoter in K562 cells. (M: DNA marker; B: blank; PC:
positive control; N: normal control; D0, day 0; D3, day 3 culture in 5-
AzadC with 0.5 lM). (B) Reverse transcription–PCR (RT-PCR) analysis
of the GAPDH status and SHP1 expression after 5-AzadC treatment. (M:
DNA marker; B: blank; N: normal control; NRT: negative control without
reverse transcriptase; D0, day 0; D3, day 3 culture in 5-AzadC with
0.5 lM).
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strated SOCS3 methylation in 27% patients with PMF, suggesting
a disease-specific SOCS3 methylation among MPN [22]. Unfortu-
nately, in our series, we had too few patients with PMF to verify this
finding.
Overall, our findings and literature review showed that MSP pri-
mer selection is important in the study of methylation as a methyla-
tion boundary may occur in some genes, in which methylation of CpG
inside the translated exonic DNA sequence, unrelated to gene silenc-
ing, may occur in normal cells. Indeed, in a study of the HIC1 gene,
CpG island methylation inside exon 3 was present in normal controls,
which was not associated with down-regulation of HIC1, and hence
unimportant for transcriptional regulation of HIC1. In contrast, CpG
sites in the 5′UTR was unmethylated in normal marrow control, but
aberrantly methylated in some AML samples, thereby emphasizing
the importance of methylation of 5′UTR, promoter-associated CpG
islands, instead of downstream CpG sites in the translated exonic
region in epigenetic regulation of gene expression [35]. Moreover, a
possible boundary between methylated and unmethylated sequence
in SOCS1 gene was suggested by the observation that methylation
was absent in the 5′UTR of SOCS1, but was detected in 85% of nor-
mal DNA using MSP primers targeting CpG sites in the 3′translated
exon 2 sequence [21]. Similarly, in SOCS3, methylation was infre-
quent using primers near the TSS in the 5′UTR, but present in 41% of
primary MPN samples when MSP primers inside the translated exon
2 sequence were used [20–22, 29]. Therefore, one has to select MSP
primers in the 5′UTR region, particularly close to the TSS, or else,
methylation unrelated to epigenetic regulation might give rise to
spuriously high frequency of gene methylation.
In contrast to the SOCS family, SHP1, another negative regula-
tor of JAK/STAT signalling, has been infrequently studied for meth-
ylation in MPN. We have shown that in myeloma, SHP1
methylation was frequent, leading to reversible SHP1 silencing and
constitutive JSK/STAT activation [24]. Here, we showed methylation
of SHP1 in primary MPN samples and K562 cells, which were veri-
fied by direct sequencing of M-MSP PCR products. Therefore,
SHP1 methylation, leading to reversible gene silencing, is impli-
cated in the constitutive activation of JAK/STAT in MPN, and hence
warrants further study in larger number of patients. Similarly, CISH
methylation is absent in MPN.
Conclusion
In conclusion, this is a comprehensive study of methylation profile of
SOCS1, SOCS2, SOCS3, CISH and SHP1 in MPN. Among these, only
SHP1 was methylated in MPN, and hence implicated in the constitu-
tive activation of JAK/STAT signalling in MPN. Moreover, careful
selection of MSP primers is important.
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Figure S1 Schematic diagram of the SOCS1 gene and the positions
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